• By ICR Secretariat
  • Posted Monday, November 21, 2022

Under FDA pressure, GSK limits use of ovarian cancer drug

https://www.biopharmadive.com/news/gsk-partial-withdraw-zejula-ovarian-cancer/636363/

GSK will stop selling the drug Zejula for some ovarian cancer patients whose disease is stable after a second line of chemotherapy, the company said Friday, following pressure from the Food and Drug Administration to pull the medicine from the market in that setting.